GSK to sell 3.2% stake in spinoff Haleon: report

Jeff J Mitchell/Getty Images News GSK ( NYSE: GSK ) reportedly plans to sell a 3.2% stake in consumer healthcare products company Haleon ( NYSE: HLN ). The sale, which is for around 300M Haleon shares, is GSK’s third in less than 12 months, potentially reducing its stake in the company to 4.2%, according to Reuters .

Haleon was created in 2019 through the merger of GSK and Pfizer’s ( PFE ) consumer products divisions. Haleon's products include Advil, Flonase and Centrum. More on GSK, Haleon plc, etc. GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference (Transcript) Haleon plc 2023 Q3 Results Earnings Call Presentation AbbVie Vs.

GSK: Dual Dominance In Pharma First RSV shots, groundbreaking gene therapy among 2024 drugs to watch China approves GSK's therapy for severe eosinophilic asthma.